New data showing cancer treatment Avastin® (bevacizumab) can extend the lives of women with advanced cervical cancer compared to chemotherapy alone has been published in the New England Journal of Medicine. In the last decade the incidence of cervical cancer has risen by approximately 15% in the UK with 2,900 women diagnosed in 2010.2 Until now there have been limited clinical advances with patients only having a choice of traditional chemotherapies.
Monday, February 24, 2014
Limiting radiation to major salivary glands in head and neck cancer patients
Avoiding the contralateral submandibular gland during radiation therapy is feasible and safe with advanced stage, node positive head and neck cancers and base of tongue lesions, according to research presented at the 2014 Multidisciplinary Head and Neck Cancer Symposium.Researchers conducted a retrospective analysis of 71 patients from two facilities - the University of Colorado Cancer Center and the Memorial Sloan-Kettering Cancer Center. The median patient age was 55, and about 50 percent of the patients were current or former smokers.
HPV-positive SCCOP patients' recurrence differs from HPV-negative patients
Patients with HPV-positive squamous cell carcinoma of the oropharynx (SCCOP) had a longer time to development of distant metastasis (DM) after initial treatment, and had more metastatic sites in more atypical locations compared to HPV-negative patients, according to research presented at the 2014 Multidisciplinary Head and Neck Cancer Symposium.Culled from records of an IRB-approved registry, the study reviewed 285 patients with stage III-IV SCCOP (originally thought to be a smoking-related head and neck cancer) treated with chemotherapy and radiation from 2002 to 2013.
Effective markers of improved patient outcome: MATH, HPV status in HNSCC
Evaluating next-generation sequencing (NGS) data and associated clinical records of head and neck squamous cell carcinoma (HNSCC) patients from several institutions, made available through The Cancer Genome Atlas (TCGA), showed that combining Mutant-Allele Tumor Heterogeneity (MATH) as a biomarker with the patient's HPV status provides an effective indicator of improved patient outcome, according to research presented at the 2014 Multidisciplinary Head and Neck Cancer Symposium.The TCGA data available for HNSCC patients included 302 patients, with 35 HPV-positive patients.
Secondary thyroid cancer more deadly than primary malignancy in young individuals
A new analysis has found that adolescents and young adults who develop thyroid cancer as a secondary cancer have a significantly greater risk of dying than those with primary thyroid cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings stress the importance of screening young cancer survivors to detect early signs of a potentially life-threatening thyroid malignancy.Thyroid cancer is one of the five most common malignancies in adolescent and young adult patients (ages 15 to 39 years).
Dishonesty and creativity: 2 sides of the same coin?
New research shows that lying about performance on one task may increase creativity on a subsequent task by making people feel less bound by conventional rules.The findings are published in Psychological Science, a journal of the Association for Psychological Science."The common saying that 'rules are meant to be broken' is at the root of both creative performance and dishonest behavior," says lead researcher Francesca Gino of Harvard Business School. "Both creativity and dishonesty, in fact, involve rule breaking.
Cognitive behavioral therapy plus hypnosis reduces fatigue in radiotherapy breast cancer patients
Breast cancer patients receiving radiotherapy showed decreased fatigue as a result of cognitive behavioral therapy plus hypnosis (CBTH), according to a study recently published in the Journal of Clinical Oncology.The study, titled, "Randomized Controlled Trial of a Cognitive-Behavioral Therapy Plus Hypnosis Intervention to Control Fatigue in Patients Undergoing Radiotherapy for Breast Cancer," was led by Guy Montgomery, PhD, Associate Professor and Director of the Integrative Behavioral Medicine Program in the Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai.
Subscribe to:
Posts (Atom)